Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim step therapy Coverage Update | Ope…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    2026 Step Therapy Medical Necessity Guidelines (selected drug classes)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Step therapy requirements for select outpatient medications (antidepressants, atypical antipsychotics, inhaled corticosteroids, and multiple sclerosis injectables); defines Step‑1 (no prior authorization) and Step‑2 (requires prior fill history) coverage conditions.

    Policy Summary
    Payerharvard pilgrim health care
    Policy2026 Step Therapy Medical Necessity Guidelines (selected drug classes)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionFor Step‑2 medications, provide evidence of prior fills (paid claim) or physician documentation of prior therapy within 180 days to obtain coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Step-1 vs Step-2Step-1 vs Step-2
    180Look-back window (days)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=2
    Rebif required fills
    MultipleTherapeutic areas

    Step Therapy Coverage Criteria

    Antidepressant step therapy

    Coverage for antidepressant products in this section follows a two-step hierarchy:

    Step-1 coverage: Bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine ER, duloxetine delayed-release capsules, escitalopram, fluoxetine, fluoxetine delayed-release, fluvoxamine, paroxetine, sertraline, venlafaxine and venlafaxine ER are on Step-1 and are covered without prior authorization.
    Step-2 coverage condition: Emsam, Fetzima, and Exxua (and their titration packs) are on Step-2 and will be covered if the member has filled for a Step-1 or Step-2 medication within the previous 180 days as evidenced by a paid claim or physician documentation.

    Atypical antipsychotic step therapy

    Coverage for atypical antipsychotics in this section follows a two-step hierarchy:

    Step-1 coverage: Aripiprazole, lurasidone, olanzapine, olanzapine-fluoxetine, quetiapine, risperidone and ziprasidone are on Step-1 and covered without authorization.
    Step-2 coverage condition: Asenapine and Fanapt (and titration packs) are on Step-2 and will be covered if the member has filled for one or more Step-1 or Step-2 medications within the previous 180 days as evidenced by a paid claim or physician documentation.

    Inhaled corticosteroid step therapy

    Coverage for inhaled corticosteroids in this section follows a two-step hierarchy:

    Step-1 coverage: QVAR is on Step-1 and covered without authorization.
    Step-2 coverage condition: Fluticasone (Diskus, HFA) is on Step-2 and will be covered if the member has filled for one or more Step-1 medications within the previous 180 days as evidenced by a paid claim or physician documentation.

    Multiple sclerosis injectable step therapy

    Coverage for multiple sclerosis injectable disease-modifying therapies follows a two-step hierarchy:

    Step-1 coverage: Avonex, Betaseron, and Plegridy are on Step-1 and covered without prior authorization.
    Step-2 coverage condition: Rebif and Rebif Rebidose (and titration packs) are on Step-2 and will be covered if the member has filled for two or more Step-1 medications within the previous 180 days as evidenced by a paid claim or physician documentation.

    No specific clinical exclusions are listed for the drug classes addressed in this policy. Coverage for Step-2 agents is conditional on documented prior therapy: the member must have evidence of prior fills (paid claim) or physician documentation showing the required Step-1 or Step-2 medication use within a 180-day look-back period in order for Step-2 products to be covered. When paid claims are not available, timely physician documentation demonstrating prior use within the 180-day window is acceptable.

    Examples of how this requirement is applied in the covered classes: antidepressant Step-2 products (Emsam, Fetzima, Exxua) require prior Step-1/Step-2 fills or documentation within 180 days; atypical antipsychotic Step-2 products (Asenapine, Fanapt and titration packs) require one or more prior fills or documentation within 180 days; inhaled corticosteroid Step-2 products (Fluticasone Diskus/HFA) require one or more prior Step-1 fills or documentation within 180 days; multiple sclerosis injectable Step-2 products (Rebif, Rebif Rebidose and titration packs) require evidence of two or more Step-1 fills or physician documentation within 180 days.

    Operational Parameters and Coding

    Prior fill look-back window
    Look-back window180 days
    Applies toAll Step-2 coverage determinations (antidepressants, atypical antipsychotics, inhaled corticosteroids, MS injectables)
    Evidence acceptedPaid claim or physician documentation within the 180-day window
    Required number of Step-1 fills for Rebif
    Required fills for Rebif>= 2 Step-1 medication fills within the prior 180 days
    Evidence acceptedPaid claims or physician documentation showing the fills
    Applies to

    Provider Requirements and Prior Authorization Rules

    Prior Authorization

    Step-2 prior therapy evidence (180-day look-back)

    Step-2 agents require evidence the member has filled a qualifying Step-1 or Step-2 medication within the previous 180 days; this must be shown by a paid claim or physician documentation to meet coverage requirements for Step-2 products.

    Note

    General step therapy rule

    Step-1 agents are covered without prior authorization. Step-2 agents will be covered only if the member has the required prior fills or physician documentation within the prior 180 days as specified for each drug class.

    Documentation Required

    Acceptable evidence of prior therapy

    Background and Scope

    This policy defines a two-step step-therapy approach for the outpatient drug classes included. Step-1 agents are considered first-line and are covered without prior authorization. Step-2 agents require documented prior therapy (paid claim) or physician documentation of prior use within the preceding 180 days to be covered.

    The policy’s purpose is to manage utilization by ensuring members try preferred, lower-step options before coverage of Step-2 medications. For antidepressants, atypical antipsychotics, and inhaled corticosteroids the requirement is generally one prior Step-1 (or Step-2 when noted) fill within 180 days; for the multiple sclerosis injectable class the Step-2 agents require evidence of two or more prior Step-1 fills within the same 180-day look-back. Physician documentation is an accepted substitute when paid claims are unavailable.

    Key Definitions

    Step-1 (definition)
    DefinitionAgents considered first-line in the step therapy sequence and covered without prior authorization.
    Examples (by class)Antidepressants: bupropion, citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine (and others); Atypical antipsychotics: aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone; Inhaled corticosteroids: QVAR; MS injectables: Avonex, Betaseron, Plegridy.
    Authorization requirementNo prior authorization required for Step-1 agents.
    Step-2 (definition)
    DefinitionAgents that require evidence of prior fills of Step-1 (or Step-2 where specified) within the previous 180 days via paid claim or physician documentation to be covered.
    Examples (by class)Antidepressants: Emsam, Fetzima, Exxua; Atypical antipsychotics: Asenapine, Fanapt (and titration packs); Inhaled corticosteroids: Fluticasone Diskus/HFA; MS injectables: Rebif and Rebif Rebidose.

    Step Therapy Operational Rules by Drug Class

    Drug / PackStepCoverage requirement
    Bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine ER, duloxetine delayed-release capsules, escitalopram, fluoxetine, fluoxetine delayed-release, fluvoxamine, paroxetine, sertraline, venlafaxine, venlafaxine ER
    Step-1
    Covered without prior authorization
    Emsam
    Step-2
    Member must have a paid claim showing a fill of a Step-1 or Step-2 antidepressant within the previous 180 days or provide physician documentation
    Fetzima
    Step-2
    Member must have a paid claim showing a fill of a Step-1 or Step-2 antidepressant within the previous 180 days or provide physician documentation
    Fetzima Titration Pack
    Step-2
    Member must have a paid claim showing a fill of a Step-1 or Step-2 antidepressant within the previous 180 days or provide physician documentation
    Exxua
    Step-2
    Member must have a paid claim showing a fill of a Step-1 or Step-2 antidepressant within the previous 180 days or provide physician documentation
    Drug / PackStepCoverage requirement
    Aripiprazole, lurasidone, olanzapine, olanzapine-fluoxetine, quetiapine, risperidone, ziprasidone
    Step-1
    Covered without prior authorization
    Asenapine
    Step-2
    Member must have a paid claim showing a fill of one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days or provide physician documentation
    Fanapt
    Step-2
    Member must have a paid claim showing a fill of one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days or provide physician documentation
    Fanapt Titration Pack B
    Step-2
    Member must have a paid claim showing a fill of one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days or provide physician documentation
    Fanapt Titration Pack C
    Step-2
    Member must have a paid claim showing a fill of one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days or provide physician documentation
    Drug / PackStepCoverage requirement
    QVAR
    Step-1
    Covered without prior authorization
    Fluticasone Propionate HFA (Fluticasone)
    Step-2
    Member must have a paid claim showing a fill of one or more Step-1 inhaled corticosteroids within the previous 180 days or provide physician documentation
    Drug / PackStepCoverage requirement
    Avonex, Betaseron, Plegridy
    Step-1
    Covered without prior authorization
    Rebif
    Step-2
    Member must have paid claims showing two or more Step-1 injectable fills within the previous 180 days or provide physician documentation
    Rebif Rebidose
    Step-2
    Member must have paid claims showing two or more Step-1 injectable fills within the previous 180 days or provide physician documentation
    Rebif Rebidose Titration Pack
    Step-2
    Member must have paid claims showing two or more Step-1 injectable fills within the previous 180 days or provide physician documentation
    Rebif Titration Pack
    Step-2
    Member must have paid claims showing two or more Step-1 injectable fills within the previous 180 days or provide physician documentation

    Policy Revision History

    2026-06-01policy_effective_dateLatest

    Policy effective date established for the '2026 Step Therapy Medical Necessity Guidelines'.

    document_title

    Document titled '2026 Step Therapy Medical Necessity Guidelines'.

    Policy Summary
    Payerharvard pilgrim health care
    Policy2026 Step Therapy Medical Necessity Guidelines (selected drug classes)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionFor Step‑2 medications, provide evidence of prior fills (paid claim) or physician documentation of prior therapy within 180 days to obtain coverage.
    SourceLink
    On This Page
    Step Therapy Coverage CriteriaOperational Parameters and CodingProvider Requirements and Prior Authorization RulesBackground and ScopeKey DefinitionsStep Therapy Operational Rules by Drug ClassPolicy Revision History
    Rebif and Rebif Rebidose (including titration packs)

    Physician documentation may substitute for a paid claim to demonstrate prior use of Step-1 or Step-2 agents within the previous 180 days when paid claims are not available.

    • Documentation must show the member filled a qualifying Step-1 or Step-2 medication within the prior 180 days.
    Denial Risk

    Antidepressant Step-2 denial condition

    Coverage for Emsam, Fetzima, and Exxua (including titration packs) will be denied unless the member has a paid claim or physician documentation showing a filled Step-1 or Step-2 medication within the prior 180 days.

    Denial Risk

    Atypical antipsychotic Step-2 denial condition

    Coverage for Asenapine and Fanapt (including Fanapt titration packs) will be denied unless the member has a paid claim or physician documentation showing a filled Step-1 or Step-2 medication within the prior 180 days.

    Denial Risk

    Inhaled corticosteroid Step-2 denial condition

    Coverage for Fluticasone (Diskus or HFA) will be denied unless the member has a paid claim or physician documentation showing a filled Step-1 medication (QVAR) within the prior 180 days.

    Denial Risk

    MS injectable Step-2 denial condition (Rebif)

    Coverage for Rebif and Rebif Rebidose (including titration packs) will be denied unless the member has paid claims or physician documentation showing two or more Step-1 medication fills within the prior 180 days.

    • Required Step-1 fills = two or more within 180 days.
    Evidence acceptedPaid claim showing prior fill(s) within 180 days or physician documentation verifying prior therapy within 180 days.